OnKure Therapeutics (NASDAQ:OKUR) versus Sol-Gel Technologies (NASDAQ:SLGL) Head to Head Comparison

Sol-Gel Technologies (NASDAQ:SLGL) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Valuation and Earnings

This table compares Sol-Gel Technologies and OnKure Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$11.71 million	1.26	-$27.24 million	($0.34)	-1.56
OnKure Therapeutics	N/A	N/A	-$77.39 million	($6.57)	-0.71

Sol-Gel Technologies has higher revenue and earnings than OnKure Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sol-Gel Technologies and OnKure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-81.75%	-27.17%	-22.49%
OnKure Therapeutics	N/A	-51.17%	-47.11%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sol-Gel Technologies and OnKure Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	0	0	2	0	3.00
OnKure Therapeutics	0	0	3	2	3.40

Sol-Gel Technologies currently has a consensus price target of $5.00, suggesting a potential upside of 845.18%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 589.41%. Given Sol-Gel Technologies’ higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than OnKure Therapeutics.

Institutional & Insider Ownership

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Sol-Gel Technologies has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Summary

Sol-Gel Technologies beats OnKure Therapeutics on 8 of the 14 factors compared between the two stocks.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

About OnKure Therapeutics

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.